Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

By sjmartinez • January 13, 2024

Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, Ytterberg SR, Hamar A, Fleischmann R. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024 Jan 12. doi: 10.1038/s41584-023-01062-9. Epub ahead of print. PMID: 38216757.

Tags: Publications, Rheumatology

Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests

Soo Hoo GW, Chang MR, Sather CC. Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests. Arch Bronconeumol. 2024 Dec 5:S0300-2896(24)00452-6.[...]

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab[...]

Decreases in hemoglobin and hematocrit may signal degree of hemorrhagic shock: retrospective evaluation in a dog model

Jahr JS, Dang J, Tong A, Iskandar S, Patel A, Grogan T, Hopster K, Driessen B, Gunther RA. Decreases in hemoglobin and hematocrit may signal[...]